SCHEMBL8223177

SCHEMBL8223177

O=C(c1ccccc1)N1CCC(C(=O)N2CCN(Cc3cccc(Cl)c3)CC2)CC1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.90
▸ KMT2A Q03164 4/20 0.71
▸ CA12 O43570 1/20 0.66
▸ CA1 P00915 1/20 0.66
▸ CA2 P00918 1/20 0.66
▸ CA9 Q16790 1/20 0.66
▸ CHRM2 P08172 1/20 0.66
▸ CHRM3 P20309 1/20 0.66
▸ TSHR P16473 4/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ MEN1 O00255 3/20 0.62
▸ MAPK1 P28482 2/20 0.62
▸ LMNA P02545 2/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ ALDH1A1 P00352 4/20 0.60
▸ KDM4E B2RXH2 4/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ ALDH1A2 O94788 1/20 0.58
▸ ALDH2 P05091 1/20 0.58
▸ ALDH3A1 P30838 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8223222 0.92 ADRB2 (0.76) ADRB2KMT2ACA12CA1CA2
SCHEMBL8228179 0.91 ADRB2 (0.77) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL8228226 0.85 ADRB2 (0.69) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL8223191 0.84 FAAH (0.82) ADRB2TSHRSMN1; SMN2KDM4E
SCHEMBL14456710 0.84 ADRB2 (0.67) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL14456711 0.83 ADRB2 (0.65) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL14456886 0.82 CYP3A4 (0.69) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL14456713 0.82 POLB (0.84) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL8223186 0.80 ADRB2 (0.62) ADRB2KMT2ATSHRSMN1; SMN2MEN1
SCHEMBL14456890 0.80 ADRB2 (0.62) ADRB2KMT2ATSHRSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007075555-A2 COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT SCHERING CORPORATION (US) 2007-07-05 — — WO disclosed
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 — — US disclosed
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 — — US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 — — US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R ADRB2 44/4885KMT2A 193/4885CA12 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback